Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Plasma Cell Myeloma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: To compare the cellular and humoral vaccine response post-transplant between the two arms by performing Elisa, and T-cell enzyme-linked immunospot (ELISPOT) assays To determine the feasibility and safety of this approach SECONDARY OBJECTIVES: To compare post-transplant recovery o...
PRIMARY OBJECTIVES: To compare the cellular and humoral vaccine response post-transplant between the two arms by performing Elisa, and T-cell enzyme-linked immunospot (ELISPOT) assays To determine the feasibility and safety of this approach SECONDARY OBJECTIVES: To compare post-transplant recovery of innate and adaptive immune cells (CD8, CD4, CD19, NK, ?? T-cells), in addition to T-cell phenotype markers between the two arms. To compare post-transplant recovery of T-regs and MDSCs between the two arms. To compare progression free survival (PFS) at 2 years post-transplant
Tracking Information
- NCT #
- NCT02700841
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Muhamed Baljevic, MD University of Nebraska
Get Well Soon